This company focuses on developing novel therapeutic agents for unmet medical needs. Their research targets specific biological pathways implicated in complex diseases. The core value lies in advancing preclinical candidates toward clinical application.
Funding
$700K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Vitiligo is a chronic autoimmune disease affecting millions worldwide, characterized by the loss of skin pigmentation due to the destruction of melanocytes. Current treatments often fail to provide a definitive cure and can be limited in their ability to address lesions across the entire body. The disease carries a significant societal stigma, leading to emotional and financial burdens for affected individuals.
Solution
Temprian Therapeutics is developing TT-01, a novel, systemically administered DNA-plasmid therapy designed to reverse the autoimmune response that causes melanocyte destruction in vitiligo patients. The therapy introduces a genetically modified DNA plasmid that modulates the immune system to protect melanocytes, potentially halting disease progression and promoting repigmentation. Preclinical studies in murine and porcine models have demonstrated the therapeutic potential of TT-01 in treating vitiligo. The company's platform technology also has potential applications for treating other autoimmune-related comorbidities, such as Hashimoto’s Disease and Alopecia Areata.
Target Audience
The primary target audience includes individuals suffering from vitiligo, as well as clinicians and dermatologists seeking more effective and systemic treatment options for this condition.
Features
- Systemic treatment via injection of a genetically modified DNA plasmid
- Targets the autoimmune response to melanocytes
- Designed to reverse the immune response and promote repigmentation
- Demonstrated efficacy in preclinical mouse and porcine models
- Potential application for other autoimmune diseases